A study showed that the lncRNA TUG1 responded to Notch signaling and promoted the self-renewal of glioma cells and that using ASOs targeting TUG1 coupled with a drug delivery system induced glioma cell differentiation and repressed tumor growth in vivo (87). Here, TUG1 is linked to central nervous system cancer.